Abstract: The present invention relates to a new medical use of fenretinide or bioactive derivatives thereof, particularly to the use of fenretinide or bioactive derivatives thereof in the preparation of a medicament for eliminating or killing tumor stem cells in a subject or for treating and/or preventing a tumor disease originating from tumor stem cells in a subject.
Type:
Application
Filed:
July 8, 2008
Publication date:
January 14, 2010
Inventors:
Ji Zhang, KanKan Wang, XiaoLing Pan, Hai Fang
Abstract: A dermatological or cosmetic preparation, which is anhydrous and contains urea, and is administered to improve the water retention capability of the stratum corneum, contains phytantriol and comprises a gel-like basis, which is essentially free of straight-chained hydrocarbons with 6 to 50 C-atoms. Compared with known such preparations, the preparation comprises markedly improved dermal sensory attributes.
Abstract: N-(2-hydroxyalkanoyl)-N,N?-dialkylureas of general formula (1) are described A-X-(A)m??(1) where A: m=0 or m=1; when m=0, X=R??, where R?? is an aliphatic, cycloaliphatic, arylaliphatic radical, C1-C18; when m=1, X=—(CH2)n—, where n is an integer from 1 and 20, preferably from 2 to 6; R is chosen among H, and alkyl radicals C1-C8, possibly substituted with halogen atoms; R? is an aliphatic, cycloaliphatic, arylaliphatic radical, C1-C18; R? is chosen among H, aliphatic, cycloaliphatic, arylaliphatic radical, C1-C18. The preparation of said compounds is described, as well as the preparation of corresponding polymers.
Type:
Grant
Filed:
November 19, 2007
Date of Patent:
January 12, 2010
Assignee:
CHORISIS S.r.l.
Inventors:
Guido Galliani, Marco Orlandi, Bruno Rindone, Alberto Terraneo
Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.
Type:
Application
Filed:
March 2, 2009
Publication date:
December 31, 2009
Applicant:
The Regents Of The University Of California
Inventors:
Bruce D. Hammock, In-Hae Kim, Christophe Morisseau, Takaho Watanabe, John W. Newman
Abstract: Composition and method for treating and/or preventing biological contamination using a biocide composition comprising at least one quaternary ammonium compound and urea. The method includes drying urea, and thereafter combining at least one quaternary ammonium compound and urea and may produce a potent biocide composition that is stable and able to chemically treat biological contamination in a variety of difficult to reach locations. Uses of the composition are also described.
Abstract: Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.
Type:
Application
Filed:
April 17, 2009
Publication date:
October 29, 2009
Inventors:
Heather K. Webb Hsu, Yi-Xin Wang, Le-Ning Zhang
Abstract: The present patent application is directed to novel fluoroethyl urea compounds and compositions and their therapeutic use in the treatment of pain and other conditions.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
October 6, 2009
Assignee:
Allergan, Inc.
Inventors:
Ken Chow, Wenkui K. Fang, Evelyn G. Corpuz, Daniel W. Gil, Michael E. Garst
Abstract: The present invention relates to compounds and the use of such compounds for increasing the efficacy of fungicides for controlling oomycete pathogen induced disease or diseases in one or more plants.
Type:
Application
Filed:
April 1, 2009
Publication date:
October 1, 2009
Applicant:
Dow AgroSciences LLC
Inventors:
Robert J. Ehr, Norman R. Pearson, Ronald Ross, JR., Christian Schobert
Abstract: The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.
Type:
Application
Filed:
December 23, 2008
Publication date:
October 1, 2009
Inventors:
Bhasker R. Aavula, Sampath-Kumar Anandan, Richard D. Gless, JR., Dinesh Patel, Gabor Rubanyi, Yi-Xin Wang, Heather K. Webb Hsu
Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.
Type:
Application
Filed:
May 5, 2006
Publication date:
August 27, 2009
Inventors:
Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gomez
Abstract: The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.
Type:
Grant
Filed:
February 26, 2002
Date of Patent:
August 11, 2009
Assignee:
McGill University
Inventors:
Bertrand J. Jean-Claude, Fabienne Dudouit, Stephanie Matheson
Abstract: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
Type:
Application
Filed:
February 2, 2009
Publication date:
August 6, 2009
Inventors:
MARSHALL L. SUMMAR, FREDERICK E. BARR, REID CARLETON THOMPSON
Abstract: One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and/or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.
Type:
Application
Filed:
October 12, 2005
Publication date:
June 25, 2009
Inventors:
Alexandros Makriyannis, Chen Li, Dai Lu
Abstract: The invention relates to a liquid concentrate for preserving cosmetic products which comprises a combination of carboxylic acid salts chosen from the salts of benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydracetic acid, formic acid or 10-undecylenic acid and alcohols chosen from 2-phenoxyethanol, benzyl alcohol, phenethyl alcohol, 1-phenoxypropan-2-ol, 3-(4-chlorophenoxy)-1,2-propanediol, chlorobutanol or 2,4-dichlorobenzyl alcohol in a solvent, where the active ingredient content is greater than 45% by weight.
Type:
Application
Filed:
January 13, 2009
Publication date:
May 14, 2009
Applicant:
AIR LIQUIDE SANTE (INTERNATIONAL)
Inventors:
Wolfgang BEILFUSS, Gisela Hahn, Klaus Weber, Ralf Gradke
Abstract: Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.
Abstract: Various medical conditions, some previously treated by injection or surgery, are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, vasodilators, botulinum toxin and minoxidil. Conditions as diverse as spider veins, erectile dysfunction, facial wrinkles, hair loss and baldness can be effectively treated with the compositions.
Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
Type:
Application
Filed:
March 16, 2005
Publication date:
January 15, 2009
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Bruce D Hammock, Takaho Watanabe, Seung Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
Abstract: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.
Type:
Application
Filed:
August 3, 2006
Publication date:
December 11, 2008
Applicant:
The Regents of The University of California Office of Technology Transfer
Abstract: The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.
Abstract: A personal care product is provided which includes a fragrance, a substituted urea and a quaternary ammonium salt. The substituted urea and quaternary ammonium salt operate together as a scent boosting system to enhance volatilization of fragrance components upon the personal care composition being first applied to human skin or hair.
Abstract: A regulator for regulating physiological functions, such as activity of increasing an intracellular calcium ion concentration, activity of promoting growth hormone secretion, activity of promoting eating, regulatory activity relating to fat accumulation, activity of ameliorating heart function and activity of stimulating gastric acid secretion, of ghrelin, which regulator comprises a fatty acid of carbon number 2-35 or its derivative, and use thereof.
Abstract: The invention relates to immunomodulatory compositions and related methods. The immunomodulatory compositions of a formula disclosed herein are useful for the prevention of sepsis and the treatment and prevention of diseases associated with inflammation and/or NOS.
Type:
Grant
Filed:
July 7, 2005
Date of Patent:
November 25, 2008
Assignees:
Genzyme Corporation, The Brigham and Women's Hospital, Inc.
Inventors:
Pericles Calias, Robert J. Miller, Andrew B. Onderdonk, Arthur O. Tzianabos
Abstract: Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A log (6) reduction in Mycobacterium terrae is achieved on the surface in less than 10 minutes. The temperature may be produced by a physical chaotrope, a chemical chaotrope (such as) boron or a boron compound or complex or a combination of chaotropic agents. Sequestering agents and enzymes maybe added.
Abstract: The present invention relates to a perfuming ingredient for body-care, detergents or softeners type consumer products that is made of microcapsules having a mean diameter of >1 to 500 ?m with a guanidine-based polyurea or polyurea/polyurethane wall that contain a perfume and to the products that contain such perfuming ingredients and microspheres.
Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
Type:
Application
Filed:
November 7, 2007
Publication date:
August 14, 2008
Inventors:
John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
Type:
Grant
Filed:
March 24, 2006
Date of Patent:
July 29, 2008
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
Abstract: The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or pegylated alpha-interferon and an IMPDH inhibitor selected from VX-148 or VX-944, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
December 25, 2007
Assignee:
Roche Palo Alto LLC
Inventors:
Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
Type:
Grant
Filed:
September 27, 2005
Date of Patent:
September 11, 2007
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft
Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Type:
Grant
Filed:
April 30, 2003
Date of Patent:
August 28, 2007
Assignees:
Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
Inventors:
John A. Tucker, Brian A. Sherer, Ying Zi Xu, Louis Brogley, Shon R. Pulley, Jon S. Jacobs, James P. Beck, Varghese John
Abstract: This Invention provides a compound of the Formula: wherein X is R1, R2, R3 and R4 are described in the specification and a pharmaceutical composition comprising the compound used for inhibiting replication of a herpes virus.
Abstract: The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.
Type:
Grant
Filed:
November 1, 2002
Date of Patent:
May 1, 2007
Assignee:
ALS Therapy Development Foundation, Inc.
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: Nitrogen containing compounds are effective as subterranean termite feeding stimulants/aggregants and as masking agents for concealing the presence of other compounds which are repellents to termites, when they are used in low concentrations, less than or equal to about 1000 ppm (0.1%, by weight). The nitrogen containing compounds may be formulated alone, or optionally in a bait or in combination with other compounds effective for controlling or marking subterranean termites.
Type:
Grant
Filed:
September 13, 2004
Date of Patent:
February 27, 2007
Assignee:
The United States of America as represented by the Secretary of Agriculture
Inventors:
Guadalupe M. Rojas, Juan A. Morales-Ramos, David R. Nimocks, III
Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.
Type:
Grant
Filed:
October 8, 2004
Date of Patent:
January 2, 2007
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
Type:
Grant
Filed:
May 2, 2003
Date of Patent:
September 12, 2006
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
Type:
Grant
Filed:
November 1, 2001
Date of Patent:
August 1, 2006
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) to processes for their preparation and to their use in medicaments, in particular for the prevention and/or treatment of cardiovascular disorders.
Type:
Grant
Filed:
November 17, 2003
Date of Patent:
July 11, 2006
Assignee:
Bayer Aktiengesellschaft
Inventors:
Erwin Bischoff, Thomas Krahn, Stephan-Nicholas Müller, Holger Paulsen, Joachim Schuhmacher, Henning Steinhagen, Wolfgang Thielemann
Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide or metronidazole, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.
Type:
Grant
Filed:
February 11, 2003
Date of Patent:
July 11, 2006
Assignee:
Bradley Pharmaceuticals, Inc.
Inventors:
Dileep Bhagwat, Bradley P. Glassman, Daniel Glassman
Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.
Type:
Grant
Filed:
May 10, 2002
Date of Patent:
June 27, 2006
Assignee:
Bradley Pharmaceuticals, Inc.
Inventors:
Dileep Bhagwat, Bradley P. Glassman, Daniel Glassman
Abstract: A chemical compound is disclosed herein for performing a complex enzymatic neutralization and fixation of formaldehyde, providing a method for instantaneous neutralization of formaldehyde vapors and offering a complete and rapid control of incidental releases, and a complete protection of workers against airborne formaldehyde during the course of their work. The compound includes alkanolamine, for instantaneous reaction with formaldehyde, and for absorbing hydrogen sulfide and carbon dioxide from the air, and a human protein, which reacts with airborne formaldehyde and forms the major enzyme involved in formaldehyde oxidation in oral mucosa. The compound also contains cyclodextrins for inclusion complexation of all the components of spent and/or unused aqueous formaldehyde solutions.
Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
Type:
Grant
Filed:
October 5, 2001
Date of Patent:
May 2, 2006
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
Abstract: The method for the diagnosis of Helicobacter pylori infection by the oral administration of defined amounts of 13C-labeled urea and examination for 13C content of blood samples removed at a defined time is effected by a) removing from 0.1 to 0.6 ml of capillary blood from the finger or ear lob of a patient or venous blood of a patient, in both cases with an empty stomach before the beginning of the test; b) administering an exact amount of from 10 to 50 mg of 13C-urea in aqueous solution with a pH value of 2 to 4 to the patient; c) again removing capillary or venous blood exactly after 10 to 15 min from the administration; and d) determining the 13C content of the blood samples by isotope ratio mass spectrometry (IRMS), and deducing the presence of Helicobacter pylori from the increase of the 13C values.
Abstract: The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become disturbed by these modifications and can result in severe consequences. The compounds of the present invention can be used to inhibit this process of nonenzymatic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compounds are also useful for preventing premature aging, spoilage of proteins in food and can prevent discoloration of teeth.
Abstract: Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include ?-alkyl-S-alkyl-homocysteine sulfoximines wherein the ?-alkyl contains 2 to 8 carbon atoms, and the S-alkyl contains 1 to 10 carbon atoms. Mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include repeated administrations of low doses of manipullators of nitrosative stress so that subject treated has increased tolerance to nitrosative stress.
Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.